+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024662
Description Jump to:
The global central nervous system therapeutics market size is expected to reach USD 254.6 million by 2030, registering a CAGR of 10.4% from 2025 to 2030. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo’s zinc finger platform to develop therapies for Alzheimer’s disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights

  • Neurodegenerative diseases are projected to witness the fastest growth with a CAGR of 11.5% over the forecast period, owing to the increasing prevalence of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis.
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2024 due to high awareness level in the region and better reimbursement scenario

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Central Nervous System Therapeutics market include:

  • Biogen
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Astra Zeneca
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Drug Class
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Central Nervous System Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Central Nervous System Therapeutics Market: Disease Business Analysis
4.1. Disease Market Share, 2024 & 2030
4.2. Disease Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
4.4. Neurovascular Diseases
4.4.1. Neurovascular Diseases Market, 2018 - 2030 (USD Million)
4.5. CNS Trauma
4.5.1. CNS Trauma Market, 2018 - 2030 (USD Million)
4.6. Mental Health
4.6.1. Mental Health Market, 2018 - 2030 (USD Million)
4.6.2. Anxiety Disorders
4.6.2.1. Anxiety Disorders Market, 2018 - 2030 (USD Million)
4.6.3. Epilepsy
4.6.3.1. Epilepsy Market, 2018 - 2030 (USD Million)
4.6.4. Mood Disorders
4.6.4.1. Mood Disorders Market, 2018 - 2030 (USD Million)
4.6.5. Psychotic Disorders
4.6.5.1. Psychotic Disorders Market, 2018 - 2030 (USD Million)
4.6.6. Others
4.6.6.1. Others Market, 2018 - 2030 (USD Million)
4.7. Neurodegenerative Diseases
4.7.1. Neurodegenerative Diseases Market, 2018 - 2030 (USD Million)
4.7.2. Alzheimer’s Disease
4.7.2.1. Alzheimer’s Disease Market, 2018 - 2030 (USD Million)
4.7.3. Parkinsosn’s Disease
4.7.3.1. Parkinsosn’s Disease Market, 2018 - 2030 (USD Million)
4.7.4. Multiple Sclerosis
4.7.4.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
4.7.5. Huntington’s Disease
4.7.5.1. Huntington’s Disease Market, 2018 - 2030 (USD Million)
4.7.6. Amytrophic Lateral Sclerosis
4.7.6.1. Amytrophic Lateral Sclerosis Market, 2018 - 2030 (USD Million)
4.7.7. Others
4.7.7.1. Others Market, 2018 - 2030 (USD Million)
4.8. Infectious Diseases
4.8.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
4.9. CNS Cancer
4.9.1. CNS Cancer Market, 2018 - 2030 (USD Million)
4.10. Others
4.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Central Nervous System Therapeutics Market: Drug Class Business Analysis
5.1. Drug Class Market Share, 2024 & 2030
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Anesthetics
5.4.1. Anesthetics Market, 2018 - 2030 (USD Million)
5.5. Anticonvulsants
5.5.1. Anticonvulsants Market, 2018 - 2030 (USD Million)
5.6. Antiemetics
5.6.1. Antiemetics Market, 2018 - 2030 (USD Million)
5.7. CNS Stimulants
5.7.1. CNS Stimulants Market, 2018 - 2030 (USD Million)
5.8. Pain Relievers
5.8.1. Pain Relievers Market, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Central Nervous System Therapeutics Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Central Nervous System Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Drug Class, Distribution Channel
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Biogen
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Otsuka Pharmaceutical Co., Ltd.
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Eli Lilly and Company
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Merck & Co., Inc.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Astra Zeneca
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Takeda Pharmaceutical Company Limited
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Novartis AG
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Teva Pharmaceutical Industries Ltd
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Johnson & Johnson Services, Inc.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Pfizer Inc.
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global central nervous system therapeutics market, by region, 2018 - 2030 (USD Million)
Table 4. Global central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 5. Global central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 6. Global central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 7. North America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
Table 8. North America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 9. North America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 10. North America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 11. U.S. central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 12. U.S. central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 13. U.S. Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 14. Canada central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 15. Canada central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 16. Canada central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 17. Mexico central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 18. Mexico central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 19. Mexico central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 20. Europe central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
Table 21. Europe central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 22. Europe central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 23. Europe central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 24. UK central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 25. UK central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 26. UK Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 27. Germany central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 28. Germany central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 29. Germany central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 30. France central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 31. France central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 32. France Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 33. Italy central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 34. Italy central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 35. Italy central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 36. Spain central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 37. Spain central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 38. Spain central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 39. Norway central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 40. Norway central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 41. Norway Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 42. Denmark central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 43. Denmark central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 44. Denmark central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 45. Sweden central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 46. Sweden central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 47. Sweden central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 48. Asia Pacific central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
Table 49. Asia Pacific central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 50. Asia Pacific central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 51. Asia Pacific central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 52. Japan central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 53. Japan central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 54. Japan central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 55. China central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 56. China central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 57. China central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 58. India central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 59. India central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 60. India central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 61. Australia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 62. Australia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 63. Australia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 64. South Korea central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 65. South Korea central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 66. South Korea central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 67. Thailand central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 68. Thailand central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 69. Thailand central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 70. Latin America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
Table 71. Latin America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 72. Latin America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 73. Latin America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 74. Brazil central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 75. Brazil central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 76. Brazil central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 77. Argentina central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 78. Argentina central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 79. Argentina central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 80. Middle East & Africa Central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
Table 81. Middle East & Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 82. Middle East & Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 83. Middle East & Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 84. South Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 85. South Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 86. South Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 87. Saudi Arabia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 88. Saudi Arabia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 89. Saudi Arabia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 90. UAE central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 91. UAE central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 92. UAE central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 93. Kuwait central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 94. Kuwait central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 95. Kuwait central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Central nervous system therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Disease and drug class (USD Million)
Fig. 10 Distribution channel outlook
Fig. 11 Competitive landscape
Fig. 12 Central nervous system therapeutics market dynamics
Fig. 13 Central nervous system therapeutics market: Porter’s five forces analysis
Fig. 14 Central nervous system therapeutics market: PESTLE analysis
Fig. 15 Central nervous system therapeutics market Disease segment dashboard
Fig. 16 Central nervous system therapeutics market: Disease market share analysis, 2024 & 2030
Fig. 17 Neurovascular diseases market, 2018 - 2030 (USD Million)
Fig. 18 CNS trauma market, 2018 - 2030 (USD Million)
Fig. 19 Mental health market, 2018 - 2030 (USD Million)
Fig. 20 Anxiety disorders market, 2018 - 2030 (USD Million)
Fig. 21 Epilepsy market, 2018 - 2030 (USD Million)
Fig. 22 Mood disorders market, 2018 - 2030 (USD Million)
Fig. 23 Psychotic disorders market, 2018 - 2030 (USD Million)
Fig. 24 Others market, 2018 - 2030 (USD Million)
Fig. 25 Neurodegenerative diseases market, 2018 - 2030 (USD Million)
Fig. 26 Alzheimer’s disease market, 2018 - 2030 (USD Million)
Fig. 27 Parkinsosn’s disease market, 2018 - 2030 (USD Million)
Fig. 28 Multiple sclerosis market, 2018 - 2030 (USD Million)
Fig. 29 Huntington’s disease market, 2018 - 2030 (USD Million)
Fig. 30 Amytrophic lateral sclerosis market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 33 CNS cancer market, 2018 - 2030 (USD Million)
Fig. 34 Others market, 2018 - 2030 (USD Million)
Fig. 35 Central nervous system therapeutics market: Drug class segment dashboard
Fig. 36 Central nervous system therapeutics market: Drug class market share analysis, 2024 & 2030
Fig. 37 Anesthetics market, 2018 - 2030 (USD Million)
Fig. 38 Anticonvulsants market, 2018 - 2030 (USD Million)
Fig. 39 Antiemetics market, 2018 - 2030 (USD Million)
Fig. 40 CNS stimulants market, 2018 - 2030 (USD Million)
Fig. 41 Pain relievers market, 2018 - 2030 (USD Million)
Fig. 42 Others market, 2018 - 2030 (USD Million)
Fig. 43 Central nervous system therapeutics market: Distribution channel segment dashboard
Fig. 44 Central nervous system therapeutics market: Distribution channel market share analysis, 2024 & 2030
Fig. 45 Hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 46 Retail pharmacies market, 2018 - 2030 (USD Million)
Fig. 47 Others market, 2018 - 2030 (USD Million)
Fig. 48 Central nervous system therapeutics market revenue, by region
Fig. 49 Regional marketplace: Key takeaways
Fig. 50 Regional marketplace: Key takeaways
Fig. 51 North America central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 U.S. country dynamics
Fig. 53 U.S. central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 Canada country dynamics
Fig. 55 Canada central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 Mexico country dynamics
Fig. 57 Mexico central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 58 Europe central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 59 UK country dynamics
Fig. 60 UK central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 61 Germany country dynamics
Fig. 62 Germany central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 63 France country dynamics
Fig. 64 France central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 65 Italy country dynamics
Fig. 66 Italy central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 67 Spain country dynamics
Fig. 68 Spain central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 69 Norway country dynamics
Fig. 70 Norway central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 71 Sweden country dynamics
Fig. 72 Sweden central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 73 Denmark country dynamics
Fig. 74 Denmark central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 75 Asia Pacific central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 76 Japan country dynamics
Fig. 77 Japan central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 78 China country dynamics
Fig. 79 China central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 80 India country dynamics
Fig. 81 India central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 82 Australia country dynamics
Fig. 83 Australia central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 84 South Korea country dynamics
Fig. 85 South Korea central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 86 Thailand country dynamics
Fig. 87 Thailand central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 88 Latin America central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 89 Brazil country dynamics
Fig. 90 Brazil central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 91 Argentina country dynamics
Fig. 92 Argentina central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 93 MEA central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 94 South Africa country dynamics
Fig. 95 South Africa central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 96 Saudi Arabia country dynamics
Fig. 97 Saudi Arabia central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 98 UAE country dynamics
Fig. 99 UAE central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 100 Kuwait country dynamics
Fig. 101 Kuwait central nervous system therapeutics market, 2018 - 2030 (USD Million)
Fig. 102 Company categorization
Fig. 103 Company market position analysis
Fig. 104 Strategic framework

Companies Mentioned

  • Biogen
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Astra Zeneca
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 140.44 Million
Forecasted Market Value ( USD ) by 2030 $ 254.6 Million
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Central Nervous System (CNS) Stimulant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Central Nervous System (CNS) Stimulant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From
Central Nervous System (CNS) Stimulant Drugs Market 2024-2028 - Product Image

Central Nervous System (CNS) Stimulant Drugs Market 2024-2028

  • Report
  • 165 Pages
  • Global
From
Anticonvulsants Market by Drug types, Indication - Global Forecast 2025-2030 - Product Image

Anticonvulsants Market by Drug types, Indication - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Anticonvulsants Global Market Report 2024 - Product Image

Anticonvulsants Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
2024 Global Forecast for Anticonvulsants, Excluding Barbiturates and Analogs (2025-2030 Outlook) - Manufacturing & Markets Report - Product Image

2024 Global Forecast for Anticonvulsants, Excluding Barbiturates and Analogs (2025-2030 Outlook) - Manufacturing & Markets Report

  • Report
  • 132 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.